Schroder Investment Management Group lifted its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 17.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 654,101 shares of the biopharmaceutical company’s stock after purchasing an additional 95,204 shares during the quarter. Schroder Investment Management Group’s holdings in Bristol-Myers Squibb were worth $40,083,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Delphi Private Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth about $108,000. Massey Quick Simon & CO. LLC lifted its position in shares of Bristol-Myers Squibb by 523.5% during the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 1,492 shares in the last quarter. Horan Capital Advisors LLC. acquired a new stake in shares of Bristol-Myers Squibb during the third quarter worth about $122,000. NuWave Investment Management LLC acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth about $119,000. Finally, Atlantic Trust LLC acquired a new stake in shares of Bristol-Myers Squibb during the second quarter worth about $111,000. 71.49% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

Shares of Bristol-Myers Squibb Co (BMY) opened at $63.95 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.43 and a debt-to-equity ratio of 0.59. Bristol-Myers Squibb Co has a 1-year low of $51.56 and a 1-year high of $70.05. The firm has a market cap of $107,913.73, a P/E ratio of 108.39, a price-to-earnings-growth ratio of 1.72 and a beta of 0.98.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The company had revenue of $5.45 billion for the quarter, compared to analysts’ expectations of $5.35 billion. During the same quarter last year, the company earned $0.63 earnings per share. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. sell-side analysts expect that Bristol-Myers Squibb Co will post 3.22 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, April 5th. This represents a $1.60 dividend on an annualized basis and a yield of 2.50%. Bristol-Myers Squibb’s payout ratio is currently 271.19%.

BMY has been the topic of several research reports. Citigroup set a $72.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Tuesday, December 5th. BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a report on Monday, December 11th. Vetr cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 target price on the stock. in a report on Friday, December 22nd. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Finally, Credit Suisse Group set a $62.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, January 22nd. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the company. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $66.79.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/schroder-investment-management-group-raises-stake-in-bristol-myers-squibb-co-bmy/1959945.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.